Akèy › Kansè pwostat › Texas › Houston
Etid klinik pou Kansè pwostat nan Houston, TX
76 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- UT MD Anderson Cancer Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
Ap rekriteFaz 1 bonè
- The University of Texas M. D. Anderson Cancer Center, Houston
Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer
Ap rekrite
- M D Anderson Cancer Center, Houston
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- Research Site, Houston
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Ap rekriteFaz 3
- Texas Oncology - Gulf Coast ( Site 8002), Houston
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- NEXT Houston, Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 3
- Renovatio Clinical, Houston
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Ap rekriteFaz 3
- Research Site, Houston
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Ap rekriteFaz 2
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Ap rekriteFaz 3
- University of Texas-MD Anderson Cancer Center ( Site 0055), Houston
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Ap rekriteFaz 3
- UT MD Anderson Cancer Center, Houston
- MD Anderson West Houston, Houston
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Ap rekriteFaz 1
- Investigational Site Number: 401, Houston
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- UT MD Anderson, Houston
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Ap rekriteFaz 3
- Houston Metro Urology (HMU), Houston
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- Research Site, Houston
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Ap rekriteFaz 3
- Research Site, Houston
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
Ap rekriteFaz 1/2
- M D Anderson Cancer Center, Houston
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
Ap rekriteFaz 2
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Ap rekriteFaz 1/2
- Oncology Consultants, P.A, Houston
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Ap rekriteFaz 2
- Oncology Consultants, Houston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Ap rekriteFaz 2
- U.T. MD Anderson Cancer Center, Houston
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
Ap rekrite
- The University of Texas MD Anderson Cancer Center, Houston
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
Ap rekriteFaz 1
- The University of Texas M. D. Anderson Cancer Center, Houston
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Ap rekriteFaz 1
- Houston Methodist Hospital, Houston
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Houston
Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
A Study of DM002 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
Ap rekriteFaz 3
- MD Anderson Cancer Center, Houston
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
Ap rekriteFaz 1/2
- M D Anderson Cancer Center, Houston
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- Houston Methodist Hospital, Houston
- ak 4 plis
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Ap rekriteFaz 2
- UT MD Anderson Cancer Center, Houston
Stem Cells for Erectile Dysfunction Post RALP
Ap rekriteFaz 1/2
- Houston Methodist, Houston
Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B. Johnson Hospital
Ap rekrite
- The University of Texas M. D. Anderson Cancer Center, Houston
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Ap rekriteFaz 2
- Michael E. DeBakey VA Medical Center, Houston
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Ap rekriteFaz 1/2
- Next Oncology - Houston, Houston
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Ap rekriteFaz 4
- UT Health Science Center, Houston
An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
Ap rekrite
- M D Anderson Cancer Center, Houston
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Ap rekriteFaz 2/3
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
Ap rekriteFaz 1/2
- Houston Methodist, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Ap rekriteEtid obsèvasyon
- Md Anderson Cancer Center, Houston
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Ap rekriteFaz 1/2
- Research Site, Houston
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Ap rekriteFaz 1
- Houston Metro Urology, Houston
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Ap rekriteFaz 3
- Lyndon Baines Johnson General Hospital, Houston
- M D Anderson Cancer Center, Houston
- MD Anderson West Houston, Houston
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- Oncology Consultants, Houston
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
Ap rekriteFaz 2
- Ben Taub General Hospital, Houston
- Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Houston
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Ap rekriteFaz 3
- Lyndon Baines Johnson General Hospital, Houston
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- ak 3 plis
Comprehensive Assessment of Cancer Theranostic Response
Ap rekrite
- M.D. Anderson Cancer Center, Houston
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #1, Houston
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Ap rekriteFaz 2
- Excel Diagnostics & Nuclear Oncology Center, Houston
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing
Ap rekriteEtid obsèvasyon
- M.D. Anderson Cancer Center, Houston
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Comprehensive Outcomes for After Cancer Health
Ap rekriteVolontè an sante akeyi
- The University of Texas MD Anderson Cancer Center, Houston
- UT Health Houston, Houston
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
Ap rekriteFaz 2
- Houston Methodist Hospital, Houston
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Ap rekriteFaz 1/2
- Houston Methodist, Houston
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN42 etid
- Seattle, WA42 etid
- Washington, DC38 etid
- Dallas, TX36 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
- Karsinòm selil skuamèz tèt ak kou47 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.